Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes.

CD5 Antigens Humans Inflammation Multiple Sclerosis / diagnosis Multiple Sclerosis, Chronic Progressive / diagnosis Multiple Sclerosis, Relapsing-Remitting
CD5L Disease duration Inflammation Multiple sclerosis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 02 08 2021
revised: 10 09 2021
accepted: 16 09 2021
pubmed: 13 10 2021
medline: 17 12 2021
entrez: 12 10 2021
Statut: ppublish

Résumé

CD5 antigen-like (CD5L) protein is a macrophage-secreted protein with roles in immunomodulation and lipid homeostasis. We compared serum CD5L levels in healthy controls to individuals diagnosed with clinically isolated syndrome, relapsing remitting (RR), secondary progressive (SP), and primary progressive (PP) multiple sclerosis (MS). CD5L was increased in SPMS relative to controls, RRMS, and PPMS. SPMS CD5L was associated with longer disease duration independent of age, sex, or disease severity. The positive relationship between CD5L and disease duration in SPMS suggests a chronic peripheral inflammatory profile compared to other subtypes, particularly PPMS, warranting investigation of functional roles for CD5L in MS.

Identifiants

DOI: 10.1016/j.msard.2021.103269 PMID: 34638097
pubmed: 34638097
pii: S2211-0348(21)00536-8
doi: 10.1016/j.msard.2021.103269
pii:
doi:

Substances chimiques

CD5 Antigens 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

103269

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Emily Kamma (E)

Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: emily.kamma@ubc.ca.

Pierre Becquart (P)

Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: pierre.becquart@ubc.ca.

Anthony Traboulsee (A)

Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: t.traboulsee@ubc.ca.

Alice Schabas (A)

Division of Neurology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: alice.schabas@vch.ca.

Irene M Vavasour (IM)

Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, Canada; International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: lees@phas.ubc.ca.

Cornelia Laule (C)

Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada; Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, Canada; International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, Canada; Department of Physics & Astronomy, Faculty of Science, University of British Columbia, Vancouver, Canada. Electronic address: claule@physics.ubc.ca.

Carles Vilariño-Güell (C)

Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: carles@can.ubc.ca.

Jacqueline A Quandt (JA)

Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada; International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, Canada. Electronic address: jquandt@pathology.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigènes CD5 › Elevated levels of serum CD5 antigen-like...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Elevated levels of serum CD5 antigen-like...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Elevated levels of serum CD5 antigen-like...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Elevated levels of serum CD5 antigen-like...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Sclérose en plaques chronique progressive › Elevated levels of serum CD5 antigen-like...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Sclérose en plaques récurrente-rémittente › Elevated levels of serum CD5 antigen-like...